Kwiatkowski W, Karolak-Wojciechowska J, Obniska J, Zejc A
Institute of General Chemistry, Technical University, Lódź, Poland.
Acta Crystallogr C. 1990 Jan 15;46 ( Pt 1):108-12. doi: 10.1107/s0108270189005421.
T = 295 K, Mo K alpha with lambda = 0.70930 A. Compound (I-6): C15H12N2O2, Mr = 252.26, monoclinic, P2(1)/c, a = 8.441 (3), b = 15.269 (1), c = 9.745 (2) A, beta = 92.34 (2) degrees, V = 1254.9 (19) A3, Z = 4, Dx = 1.335 g cm-3, mu = 0.85 cm-1, F(000) = 528, R = 0.0345 for 1682 observed reflections. Compound (I-10): C16H14N2O2, Mr = 266.30, monoclinic, P2(1)/n, a = 11.637 (1), b = 5.793 (1), c = 20.778 (2) A, beta = 105.26 (1) degrees, V = 1351.3 (25) A3, Z = 4, Dx = 1.309 g cm-3, mu = 0.82 cm-1, F(000) = 560, R = 0.0379 for 1840 observed reflections. Compound (I-11): C16H13C1N2O2, Mr = 300.74, triclinic, P1, a = 9.076 (3), b = 9.366 (1), c = 10.477 (3) A, alpha = 118.27 (2), beta = 93.85 (2), gamma = 105.26 (1) degree, V = 737.2 (15) A3, Z = 2, Dx = 1.350 g cm-3, mu = 2.61 cm-1, F(000) = 312, R = 0.0528 for 2018 observed reflections. The three N-pyridyl-2-phenylsuccinimides [N-(3-methyl-2-pyridyl)-2-p-chlorophenylsuccinimide (I-11); N-(3-methyl-2-pyridyl)-2-phenylsuccinimide (I-10) and N-(3-pyridyl)-2-phenylsuccinimide (I-6)], examined by means of X-ray structure analysis, have been previously subjected to extensive pharmacological screening, with regard to their anticonvulsive activity. Pharmacological properties of the compounds examined are clearly connected with the conformation of the molecules. The conformation of the molecules of biologically active derivatives (I-10) and (I-11) differs from the conformation of the inactive molecule of (I-6). This difference involves relative positioning of the pyridyl ring and the succinimide moiety. The Cl atom in (I-11) has only a minor effect on the conformation and geometry of the molecule in comparison with (I-10).
温度T = 295 K，钼Kα辐射，波长λ = 0.70930 Å。化合物（I - 6）：C₁₅H₁₂N₂O₂，Mr = 252.26，单斜晶系，P2(1)/c，a = 8.441(3)，b = 15.269(1)，c = 9.745(2) Å，β = 92.34(2)°，V = 1254.9(19) ų，Z = 4，Dx = 1.335 g cm⁻³，μ = 0.85 cm⁻¹，F(000) = 528，对于1682个观测反射，R = 0.0345。化合物（I - 10）：C₁₆H₁₄N₂O₂，Mr = 266.30，单斜晶系，P2(1)/n，a = 11.637(1)，b = 5.793(1)，c = 20.778(2) Å，β = 105.26(1)°，V = 1351.3(25) ų，Z = 4，Dx = 1.309 g cm⁻³，μ = 0.82 cm⁻¹，F(000) = 560，对于1840个观测反射，R = 0.0379。化合物（I - 11）：C₁₆H₁₃ClN₂O₂，Mr = 300.74，三斜晶系，P1，a = 9.076(3)，b = 9.366(1)，c = 10.477(3) Å，α = 118.27(2)，β = 93.85(2)，γ = 105.26(1)°，V = 737.2(15) ų，Z = 2，Dx = 1.350 g cm⁻³，μ = 2.61 cm⁻¹，F(000) = 312，对于2018个观测反射，R = 0.0528。通过X射线结构分析研究的三种N - 吡啶基 - 2 - 苯基琥珀酰亚胺[N - (3 - 甲基 - 2 - 吡啶基) - 2 - 对氯苯基琥珀酰亚胺（I - 11）；N - (3 - 甲基 - 2 - 吡啶基) - 2 - 苯基琥珀酰亚胺（I - 10）和N - (3 - 吡啶基) - 2 - 苯基琥珀酰亚胺（I - 6）]，先前已针对其抗惊厥活性进行了广泛的药理筛选。所研究化合物的药理性质与分子构象明显相关。生物活性衍生物（I - 10）和（I - 11）的分子构象与无活性分子（I - 6）的构象不同。这种差异涉及吡啶环和琥珀酰亚胺部分的相对位置。与（I - 10）相比，（I - 11）中的Cl原子对分子的构象和几何形状只有轻微影响。
